Triple negative breast cancer (TNBC) accounts for 15–20% of breast cancer cases in the United States. Systemic neoadjuvant chemotherapy (NACT), with or without immunotherapy, is the current standard of care for patients with early-stage TNBC. However, u
Recent phase III clinical studies have demonstrated that combining neoadjuvant chemotherapy with immune checkpoint inhibitors (ICI) can improve the response rate in early-stage triple-negative breast cancer (TNBC) patients. However, the addition of ICI can introduce unnecessary (and potentially permanent)...
III. Addressing challenges of chimeric antigen receptor T cell therapy with combinatorial chemotherapies The challenges faced by CAR T cell therapy have hindered the success of clinical trials and ultimately the number of FDA approvals, especially for solid and brain tumors for which no therapies hav...
Triple negative breast cancer (TNBC) accounts for 15–20% of breast cancer cases in the United States. Systemic neoadjuvant chemotherapy (NACT), with or without immunotherapy, is the current standard of care for patients with early-stage TNBC. However, up to 70% of TNBC patients have significa...
TNBC models. In an orthotopic EMT6 TNBC model, the gel vaccine significantly reduced the tumor growth rate and improved the survival of mice compared to controls, with 30% of tumors being eradicated (Supplementary Fig.20). These results were mimicked in an orthotopic EO771 TNBC model, where ...
In the TNBC subset, the probability rate that the combination is superior to the control arm was 98.4%, with an 80.6% rate that it will be successful in a phase 3 study. Finally, in the HR-positive/HER2-negative group, the probability success rate versus the control arm ...
Whatever the dose of chemotherapy drugs may be, any dose is too high. Chemo drugs create a broad array of health problems. Unfortunately, the modern treatment for each symptom is another dose of drugs − each with more side effects to be treated. Take a look at a few drugs, their side...
Our success rate for establishing cancer organoids from TNBC patient samples after NAC was 83% (10 out of 12 samples), and for organoids from normal mammary tissues, it was 100% (2 out of 2 samples). These organoid lines closely recapitulated the histopathology, genetic and transcriptional ...